TNXP Valuation Debate: Conflicting Claims Post Tonmya FDA Approval

The Reddit discussion on TNXP’s valuation presents conflicting arguments. Proponents claim TNXP is undervalued citing Tonmya’s FDA approval (first new fibromyalgia drug in 15 years), cash reserves, buyback plan, and short float [0]. However, most of these claims remain unverified [2,3,4]. Tonmya uses the same active ingredient as Flexeril but has a sublingual formulation with faster absorption and reduced metabolite production [1]. While the FDA approval is a positive catalyst, TNXP’s financial metrics are concerning: negative P/E (-2.08x), ROE (-37.82%), and net profit margin (-540.64%) [0]. The company has strong liquidity (current ratio 7.53) but a history of poor performance (-99.8% drop over 3 years) [0].

1. Tonmya’s sublingual formulation differentiates it from oral Flexeril, though both use cyclobenzaprine [1].
2. Most pro-investment claims from Reddit (cash reserves, buyback plan, short float) lack verification [2,3,4].
3. TNXP has strong liquidity but terrible profitability, indicating operational challenges [0].
4. Analyst consensus is buy (85.7% buy ratings) but historical performance is abysmal, creating mixed sentiment [0].

• Tonmya’s FDA approval for fibromyalgia may lead to prescription preference over off-label Flexeril [1].
• Market exclusivity until 2034 (potential extension to 2044) provides a competitive edge [1].
• Strong liquidity (current ratio 7.53) allows for operational flexibility [0].

• Unverified scam allegations raise credibility concerns [6].
• Poor financial metrics (negative margins, ROE) indicate long-term viability risks [0].
• Most pro-investment claims (cash reserves, buyback, short float) are unverified [2,3,4].
• Competition from generic Flexeril may limit Tonmya’s market share [1].

• Current Price
  : $15.08 (+7.1% 1-day) [0]
• Market Cap
  : $132.19M [0]
• Tonmya Details
  : Sublingual cyclobenzaprine, FDA-approved for fibromyalgia, market exclusivity until 2034 [1]
• Financial Metrics
  : P/E -2.08x, ROE -37.82%, net margin -540.64%, current ratio 7.53 [0]
• Unverified Claims
  : Cash reserves ($190M), $35M buyback plan, 20% short float [2,3,4]
• Sentiment
  : Mixed (analyst buy consensus vs. poor historical performance and unverified allegations) [0]

All information is for decision-making context only and not investment advice.